Xeljanz

This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.

Gilead and Galapagos JAK contender scores in RA trial

The first JAK inhibitor on the market is Pfizer’s Xeljanz (tofacitinib) and already earns in excess of $1bn a year in RA revenues.

New data keeps AbbVie’s star pipeline therapies on track

follow-up to its marketed JAK inhibitor Xeljanz (tofacitinib). ... And for good measure Pfizer is developing a topical formulation of Xeljanz for atopic dermatitis, an approach also taken by Torii Pharma with its phase II candidate JTE-052.
BMS psoriasis drug hits the mark in phase II

Pfizer’s Xeljanz (tofacitinib) has been approved for psoriatic arthritis but was turned down by the FDA for psoriasis in 2015.
Gilead, Galapagos JAK inhibitor clears phase II test

related. First-to-market JAK inhibitor Xeljanz (tofacitinib) from Pfizer has already achieved $1bn-plus sales in RA, and with Olumiant somewhat hamstring by the safety issue on its label analysts
Pfizer CEO reckons rebates will disappear, and that’s a positive

Pfizer’s chief executive Ian Read (pictured below) has said that he expects drug price rebates will eventually disappear in the US, and that could give drugs like arthritis drug Xeljanz ... formulary is offering a large rebate – something that Read
Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar

Will Pfizer spark price war with its Herceptin biosimilar?

More from news
Approximately 20 fully matching, plus 45 partially matching documents found.

Pharma deals during September 2013

antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Infographic: RA Perceptions

The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’ s Otezla (apremilast) and Pfizer’ s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with
Infographic: RA Perceptions

The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’ s Otezla (apremilast) and Pfizer’ s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with
Brand leaders in RA will lose market share, predict rheumatologists

JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product. ... The EMA’ s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Client Services Director – Medical Education Agency – North West...: Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Add my company

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...